Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy
Implications for antiarrhythmic therapy and driving restrictions
Nahum A. Freedberg, MDa,b,
John N. Hill, MDa,
Richard I. Fogel, MD, FACCa,
Eric N. Prystowsky, MD, FACCa the CARE Group
a The Care Group, Indianapolis, Indiana, USA
b Nahum A. Freedberg’s current address: Cardiology Department, Ha’Emek Medical Center, Afula 18101, Israel
View larger version (19K):
[in a new window]
|
Figure 1 Actuarial freedom from initial versus second ICD therapy. ICD = implantable cardioverter defibrillator.
|
|
View larger version (30K):
[in a new window]
|
Figure 2 Predictors for actuarial freedom from initial ICD therapy. (A) left ventricular ejection fraction; (B) presenting arrhythmia; (C) antiarrhythmic drug use. AAD = antiarrhythmic drugs; CA = cardiac arrest; EF = left ventricular ejection fraction; ICD = implantable cardioverter defibrillator; VT = ventricular tachycardia.
|
|
View larger version (29K):
[in a new window]
|
Figure 3 Presenting symptoms versus first implantable cardioverter defibrillator therapy symptoms in patients with sustained monomorphic ventricular tachycardia. ICD = implantable cardioverter defibrillator.
|
|
View larger version (27K):
[in a new window]
|
Figure 4 Symptoms with first ICD therapy versus second ICD therapy (patients who had only one ICD therapy were excluded). ICD = implantable cardioverter defibrillator.
|
|
View larger version (23K):
[in a new window]
|
Figure 5 Correlation between cycle length of ventricular tachycardia preceding first and second ICD therapy. ICD = implantable cardioverter defibrillator; VT = ventricular tachycardia.
|
|
|
